Codexis Logo - September 2023.png
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
May 14, 2024 06:00 ET | Codexis, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an...
Codexis Logo - September 2023.png
Codexis Reports First Quarter 2024 Financial Results
May 02, 2024 16:05 ET | Codexis, Inc.
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer ...
Codexis Logo - September 2023.png
Codexis to Report First Quarter 2024 Financial Results on May 2
April 18, 2024 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first...
Codexis Logo - September 2023.png
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
April 11, 2024 07:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s...
Codexis Logo - September 2023.png
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 28, 2024 16:05 ET | Codexis, Inc.
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected...
Codexis Logo - September 2023.png
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
February 26, 2024 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an...
Codexis Logo - September 2023.png
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
February 26, 2024 08:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health...
Damha_Masad_Headshot
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
February 20, 2024 08:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD,...
Codexis Logo - September 2023.png
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
February 14, 2024 16:05 ET | Codexis, Inc.
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth...
Codexis Logo - September 2023.png
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
February 13, 2024 16:05 ET | Codexis, Inc.
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and...